CELZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Creative Medical Technology Holdings Inc (CELZ) is not a strong buy at the moment for a beginner, long-term investor. While there are positive developments such as regulatory approval for its CELZ Biodefense platform and promising results from its Ultrasome pilot study, the lack of clear bullish technical indicators, absence of significant trading trends, and no recent congress trading data suggest a cautious approach. Additionally, the stock's price trend and analyst rating are not compelling enough to recommend immediate action.
The MACD histogram is positive but contracting, indicating weakening momentum. The RSI is neutral at 51.633, showing no overbought or oversold conditions. Moving averages are converging, suggesting indecision in price direction. Key support and resistance levels are near the current price, with the pivot at 2.228, R1 at 2.414, and S1 at 2.042. Overall, the technical indicators do not provide a strong buy signal.
Regulatory approval for CELZ Biodefense platform to support veterans using an AI-enabled mobile app.
Promising pilot study results for Ultrasome therapy, showing 93% of patients with clinically meaningful improvements in osteoarthritis treatment.
Capital efficiency as the company plans to implement its projects without additional fundraising.
The stock's price dropped by 0.45% during the regular market session, indicating weak short-term sentiment.
Analysts highlight potential but no immediate catalysts for a significant price surge.
No significant hedge fund or insider trading trends to support bullish sentiment.
No financial data available for the latest quarter.
Roth Capital has a Buy rating with a $20 price target, citing the broad applicability of Ultrasome therapy. However, the stock's current price of $2.23 shows a significant gap from the target, and no recent updates from other analysts are available.
